X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.

New government data show medicine price growth continues to decline

By Holly Campbell  |    January 18, 2019
Last year, the U.S. Food and Drug Administration approved a record 59 new treatments and cures. During this incredible period of innovation, medicine price growth continued to slow dramatically.   Read More

New whitepaper identifies limitations in using ICER’s “potential budget impact” work to guide private payer budget decisions

By Holly Campbell  |    January 18, 2019
A new whitepaper authored by Bruce Pyenson, F.S.A., M.A.A.A. and colleagues from Milliman explains why Institute for Clinical and Economic Review (ICER) potential budget impact analyses are not...   Read More

ICYMI: New study reinforces dangers of proposed IPI model

By Nicole Longo  |    January 15, 2019
Stakeholder after stakeholder has raised concerns that the Department of Health and Human Services’ proposed International Pricing Index (IPI) Model would put patient access to medicines in...   Read More

PhRMA comments to administration on International Pricing Index Model

By Nicole Longo  |    January 3, 2019
As 2018 came to a close, PhRMA submitted comments on the administration’s proposed International Pricing Index (IPI) Model for Medicare Part B medicines. The comments highlighted concerns and...   Read More

10 things you should know about medicine spending and costs

By Holly Campbell  |    January 2, 2019
Discussions about costs are important. Too often patients struggle to afford the medicines they need. Our industry is committed to working with policymakers on solutions that enhance the...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates